Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENITY: LY3074828 in Active Crohn's Disease
2016-002204-84Phase 2Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing LY3074828 with Placebo (2 arms). Primary endpoint: Endoscopic response at Week 12. Status: unknown.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-002204-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002204-84.